Official ESCRS | European Society of Cataract & Refractive Surgeons


Visual function of extended-depth-of-focus intraocular lens in glaucomatous eye

Search Title by author or title

Session Details

Session Title: Combined Cataract Surgery & Practice Styles

Session Date/Time: Sunday 15/09/2019 | 14:00-16:00

Paper Time: 14:36

Venue: Free Paper Forum: Podium 2

First Author: : Y.Ota JAPAN

Co Author(s): :    H. Bissen-Miyajima   M. Hirasawa   K. Minami   K. Yuki                    

Abstract Details


To retrospectively access the visual function with extended depth-of-focus intraocular lenses (EDOF IOLs) in glaucomatous eyes.


Department of Ophthalmology, Tokyo Dental College Suidobashi Hospital  


Eleven eyes with primary open angle glaucoma under good control of intraocular pressure (12.8±2.1mmHg) and mean deviation (MD) higher than -10dB were included. EDOF IOLs (ZXR00V, ZXV 150-375: Johnson&Johnson Vision) were implanted following cataract removal. Uncorrected and distance-corrected logMAR visual acuities (UCVA, DCVA) at 5, 1, and 0.5m, contrast sensitivity (CS), as well as the quality of vision based on questionnaire 3 months following the surgery were evaluated. This was then compared to results from 22 non-glaucomatous eyes (control). In glaucomatous eyes, pre-operative and postoperative MDs, measured by Humphrey Visual Field 30-2 automated perimetry testing, were compared.


The mean UCVA / DCVA were -0.06±0.08 / -0.14±0.05 for 5m, 0.01±0.13 / -0.04±0.10 for 1m, and 0.08±0.07 / 0.09±0.09 for 0.5m. There were no significant differences between glaucomatous and control eyes (UCVA: P>0.13, DCVA: P> 0.49). The CS at all spatial frequencies and the subjective quality of vision did not differ significantly between glaucomatous contorol eyes (P>0.21 and 0.10, respectively). The MD was -3.81±2.87dB preoperatively and -4.78±2.99dB postoperatively, and no significant differences were found (P=0.85).


The favorable clinical outcomes following the implantation of EDOF IOLs were found in the early-stage open angle glaucoma.

Financial Disclosure:

gains financially from product or procedure presented, research is funded, fully or partially, by a competing company, receives consulting fees, retainer, or contract payments from a competing company

Back to previous